(PDF) Dual Inhibition of PI3K and mTORC1/2 Signaling by

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Clinical Cancer Research - United States

doi 10.1158/1078-0432.ccr-10-1102

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

September 30, 2010

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics

Cancer Research

English

The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma

Cancer Research

English

Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines

Drug Design, Development and Therapy

Pharmaceutical Science

English

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer

International Journal of Oncology

Cancer Research

English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica

English

Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English

DDR1 Inhibition as a New Therapeutic Strategy for Colorectal Cancer

Molecular and Cellular Oncology

Cancer Research

Molecular Medicine

English

Therapeutic Potentials of İnhibition Jumonji C Domain Containing Demethylases in Acute Myeloid Leukemia

Turkish Journal of Haematology

English

Dual Roles of EZH2 in Acute Myeloid Leukemia

Journal of Experimental Medicine

English